Macquarie leads $300 million senior secured credit facility to Vertex Pharmaceuticals
01 Jul 2014
Macquarie arranged and led the $300 million senior secured credit facility to Vertex Pharmaceuticals (NASDAQ:VRTX), a developer, manufacturer and marketer of drugs that treat the life-threatening disease cystic fibrosis. The credit facility was structured by Macquarie in order to fund future operations and development as Vertex seeks to gain regulatory approval for a drug that could potentially treat approximately one third of the global cystic fibrosis population.
Macquarie acted as arranger and underwrote the full facility. Macquarie had previously provided a capital lease facility to the company in 2013.